Bionano Genomics (BNGO) stock surged 7.64% in the pre-market session on Monday.
The rally comes after the company announced positive results from a study at Johns Hopkins University School of Medicine, showing that its Optical Genome Mapping (OGM) technology outperformed multiple cytogenetic assays in the analysis of bone and soft tissue tumors. Key findings included: - OGM detected 100% of variants found by standard techniques like karyotyping and FISH - OGM was more sensitive, detecting diagnostic variants missed by karyotyping in 74% of failed/negative cases - Combined with next-generation sequencing, OGM found diagnostic variants in ~98% of cases, substantially higher than standard methods The researchers highlighted OGM's potential to qualify more patients for targeted therapies or clinical trials based on the additional variants detected.
The positive study results suggest increasing adoption potential for Bionano's OGM technology beyond blood cancers into solid tumor analysis as well.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。